Andrew Gengos is Chief Financial Officer of Terns Pharmaceuticals, Inc.. Currently has a direct ownership of 15,000 shares of TERN, which is worth approximately $58,500. The most recent transaction as insider was on Jun 16, 2025, when has been sold 5,000 shares (Common Stock) at a price of $3.95 per share, resulting in proceeds of $19,750. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 15K
n/a 3M change
n/a 12M change
Total Value Held $58,500

Andrew Gengos Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 16 2025
BUY
Open market or private purchase
$19,750 $3.95 p/Share
5,000 Added 25.0%
15,000 Common Stock
Jun 13 2025
BUY
Open market or private purchase
$37,400 $3.74 p/Share
10,000 Added 50.0%
10,000 Common Stock

Also insider at

CYT
Cyteir Therapeutics, Inc. Healthcare
ATHA
Athira Pharma, Inc. Healthcare
AG

Andrew Gengos

Chief Financial Officer
Lexington, MA

Track Institutional and Insider Activities on TERN

Follow Terns Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TERN shares.

Notify only if

Insider Trading

Get notified when an Terns Pharmaceuticals, Inc. insider buys or sells TERN shares.

Notify only if

News

Receive news related to Terns Pharmaceuticals, Inc.

Track Activities on TERN